Vein graft failure following bypass surgery is a frequent and important clinical problem. The vascular injury caused by arterialization is responsible for vein graft intimal hyperplasia, a lesion generated by medial smooth muscle cell proliferation and migration into the intima, increased extracellular matrix deposition, and formation of a thick neointima. Development of the neointima into a typical atherosclerotic lesion and consequent stenosis ultimately result in vein graft failure. Endothelial damage, inflammation, and intracellular signaling through mitogenactivated protein kinases (MAPKs) have been implicated in the early stages of this process. We therefore investigated the effects of topical inhibition of ERK-1/2 MAPK activation on vascular cell proliferation and apoptosis, and on the inflammatory response in a canine model of vein graft arterialization. For this purpose, vein grafts were incubated with the MEK-1/2 inhibitor, UO126, ex vivo for 30 min before grafting. This treatment effectively abolished arterializationinduced ERK-1/2 activation, decreased medial cell proliferation, and increased apoptosis. UO126 treatment also inhibited the vein graft infiltration by myeloperoxidase-positive inflammatory cells that follows vein graft arterialization. Thus, topical ex vivo administration of MAPK inhibitors can provide a pharmacological tool to prevent or reduce the vascular cell responses that lead to vein graft intimal hyperplasia and graft failure.
Studies in several models aimed at characterizing the development of intimal hyperplasia after arterial injury have highlighted the importance of a number of growth factors and cytokines, including FGF-2, PDGFs, and angiotensin II (5, 6) . Many of these agents, as well as mechanical, oxidative, and shear stress, stimulate quiescent smooth muscle cells in the vessel wall by activating intracellular signaling. Among these, the mitogen-activated protein kinases (MAPKs) play a pivotal role. The MAPKs, which include the extracellular signal-regulated kinases 1 and 2 (ERK-1/2), p38 MAPK , and the c-jun N-terminal kinases (JNKs), are a family of highly conserved enzymes that relay extracellular signals from the cell's cytoplasm to the nucleus (7, 8) .
To study the role of MAPKs in vascular remodeling, investigators have used the rat carotid artery balloon injury model to determine the kinetics of MAPK activation (6, 9, 10) and the effects of MAPK inhibition on vascular remodeling (10, 11) . We have shown that mechanical injury of cultured endothelial cells induces a strong activation of ERK-1/2, which controls cell migration. ERK-1/2 activation and cell migration in response to injury require endogenous FGF-2 (12, 13) . ERK-1/2 activation also occurs in mechanically wounded vascular smooth muscle cells in vitro (unpublished results). We found that in the vascular smooth muscle cells of vein grafts, MAPKs are activated rapidly following arterialization and undergo a bimodal wave of activation that precedes the onset of cell proliferation in the vessel wall (14) .
The ERK-1/2 pathway has been implicated in the control of cell proliferation, migration, and programmed death (15) . Therefore, we investigated the effects of ERK-1/2 inhibition on cell proliferation and programmed death in arterialized vein grafts. We also studied the effects of MAPK inhibition on myeloperoxidase (MPO) and C reactive protein (CRP) expression, two hallmarks of the early inflammatory response to vein graft arterialization. To this end, we incubated excised veins in saline solution containing UO126, a synthetic inhibitor of the ERK-1/2 pathway (16), before grafting into the arterial system. We then studied the effect of ERK-1/2 inhibition on cell proliferation, apoptosis, MPO, and CRP expression.
MATERIALS AND METHODS

Operative procedure
Bilateral carotid artery bypasses were performed on 9 purpose-bred adult mongrel dogs (∼25 kg) using reversed autologous external jugular vein as previously described (14) . The external jugular vein (EJV) was harvested, flushed with Plasmalyte solution, and divided into two segments. One segment was placed in phosphate-buffered saline (PBS) containing 80 μmol/l of UO126, while the other segment was placed in 0.8% (v/v) DMSO (vehicle) in PBS as a control. This concentration of UO126 was chosen based on dose-response tests with excised canine saphenous veins (Supplemental Fig. 1 ). Each vein segment was incubated in its respective solution for 30 min at room temperature before grafting to one carotid artery using end-to-side vascular anastomoses with 7-0 prolene suture. Once the vein graft was in place, the carotid artery was ligated and divided between the vein graft anastomoses. Three hours, 8 h, 1 day, or 4 days later, the dogs were anesthetized and the vein graft segments were harvested as previously described (14) . A segment of each vein graft was fixed in formaldehyde (3.7%) for immunohistochemical examination, and the remainder was placed in lysis buffer (see below). Segments of femoral vein were also harvested as controls before sacrifice. All operations were performed without a fatality, and all vein grafts were patent at the time of harvest. These times were chosen in order to monitor early signs of activation of intracellular signaling pathways and 
Sample processing
Immediately after excision, the vein grafts and control veins were processed as previously described (17) . Briefly, the vein samples were placed into ice-cold lysis buffer (50 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA, 10% glycerol, 1% Triton X-100, 25 mmol/l NaF) supplemented with complete protease inhibitor cocktail (Roche, Indianapolis, IN) and 1 mmol/l of the tyrosine phosphatase inhibitor sodium orthovanadate. All the samples were finely minced with sterile scissors, homogenized by sonication on ice, and centrifuged in a refrigerated Eppendorf centrifuge (14,000 rpm, 20 min). The supernatants were assayed for protein content by the bicinchoninic acid (BCA) method (Pierce, Rockford, IL).
Western blotting
Equal amounts of vein extract protein were electrophoresed in sodium dodecyl sulfate (SDS)/10% polyacrylamide gels and blotted onto PVDF membranes (Millipore, Bedford, MA). The membranes were incubated with pretested dilutions of antibodies to the active (phosphorylated) forms of ERK-1/2 or Akt (Cell Signaling Technology, Beverly, MA) or to proliferating cell nuclear antigen (PCNA) (LabVision, Fremont, CA), myeloperoxidase (MPO) (Chemicon International, Temecula, CA), or CRP (Bethyl Laboratories, Montgomery, TX). As a control for equal loading and transfer, the membranes were stripped and reprobed with antibodies to ERK-2 (Santa Cruz Biotechnology, Santa Cruz, CA) or total Akt (Cell Signaling Technology). The protein blots were incubated with horseradish peroxidase-labeled anti-rabbit, anti-mouse, or anti-goat IgG antibodies (Amersham Pharmacia Biotech, Piscataway, NJ), and antigen-antibody complexes were detected by enhanced chemiluminescence (Lumilight, Roche). Quantitative analysis of the immunoreactive bands was performed by scanning densitometry with Kodak (Rochester, NY) 1D Image Analysis software. ERK-1/2 activation was quantitated as previously described (14) .
Immunohistochemical analysis
For immunodetection of active ERK-1/2 or Akt, paraffin-embedded cross sections (4-6 μm) of the veins were processed with the ABC staining kit (Santa Cruz Biotechnology) using anti-active ERK-1/2 monoclonal antibody or anti-phospho-Akt polyclonal antibody (Cell Signaling Technology), respectively. Cell proliferation was analyzed by staining with monoclonal antibodies to PCNA, a 36-kDa protein that accumulates in the nucleus of cells committed to overcoming the G1 phase of the cell cycle (REF). Immunodetection of MPO was performed using specific antibodies to MPO (Chemicon International). To detect apoptotic cells, the sections were stained for ladderized DNA using the terminal deoxynucleotidyl transferasemediated 2′-deoxyuridine 5′-triphosphate nick end labeling (TUNEL) assay (Oncogene Research Products, Boston, MA). The sections were counterstained with the nuclear stain Hoechst 33342 and analyzed with a fluorescence microscope (Zeiss Axioskop 2, Carl Zeiss, Thornwood, NY). To compute the apoptotic index, the number of TUNEL-positive cells was divided by the total
Page 3 of 13 (page number not for citation purposes)
number of cells in high-powered fields at the 3, 6, 9, and 12 o'clock positions of each specimen's cross section (n=3 per time point). Where indicated, sections were also immunostained with monoclonal antibody to α-SMC actin (Sigma, St. Louis, MO).
Transmission electron microscopy
Vein samples fixed in 3% glutaraldehyde at 4°C and postfixed with 1% OsO 4 were dehydrated and embedded in Eponate 12 (Ted Pella, Inc., Redding, CA). Ultrathin sections counterstained with uranyl acetate and lead citrate were examined with a Zeiss EM 10 transmission electron microscope operated at 60 KV.
Statistical analysis
The results were analyzed using the SPSS statistical software package (version 11, Chicago, IL). ANOVA was used to analyze differences at various time points within groups, and the Student's t test was used for comparison between groups at each time point. P ≤ 0.05 were considered significant. Results are expressed as means ± SE, unless otherwise stated.
RESULTS
Pretreatment of vein grafts with UO126 inhibits arterialization-induced activation of ERK-1/2
We have previously shown that vein graft arterialization results in two waves of ERK-1/2 activation: one that peaks at 3 h and one at 4 days after vein grafting (14) . To inhibit the activation of the ERK-1/2 pathway, we incubated vein segments with UO126 (80 μmol/l), a specific inhibitor of MEK1/2, for 30 min at room temperature before implantation. This incubation time reflects the average time between harvesting and grafting of saphenous veins in most vascular bypass procedures.
Preincubation with UO126 effectively suppressed early (3 h) ERK-1/2 activation in the arterialized vein grafts to baseline levels (Fig. 1A, 1B) . Decreased ERK-1/2 activation was also observed at 4 days in spite of the relatively short-lived (6-8 h) efficacy of UO126 (18) (data not shown). This finding suggests that the second wave of MAPK activation following vein graft arterialization (14) is controlled by the initial ERK-1/2 activation.
To rule out potential, nonspecific effects of UO126 on signaling pathways other than ERK-1/2, we characterized its effect on Akt activation at 3 h after grafting. Vein graft arterialization resulted in Akt activation, which was not inhibited by UO126 (Supplemental Fig. 2) . Thus, the effect of UO126 appeared to be highly selective as expected based on its in vitro activity (16) .
Pretreatment of vein grafts with UO126 inhibits arterialization-induced cell proliferation and induces sustained apoptosis in medial cells
The ERK-1/2 pathway controls cell proliferation induced by a variety of peptide growth factors (7) . We have previously observed that vein graft arterialization induces smooth muscle cell proliferation (14) . Therefore, we tested whether inhibition of the ERK-1/2 pathway affects medial cell proliferation following vein graft arterialization (14) . For this purpose, we characterized the expression of PCNA, a marker of cells committed to cell cycle progression, in vein grafts pretreated with UO126. As shown in Fig. 2A and 2B , inhibition of the ERK-1/2 pathway resulted in dramatic down-regulation of PCNA expression, indicating that this MAPK controls smooth muscle cell proliferation in vein graft.
Because individual signaling pathways control a variety of biological responses (8), we investigated whether inhibition of the ERK-1/2 pathway also affects programmed cell death (apoptosis). The results (Fig. 2C) showed that inhibition of ERK-1/2 activation by UO126 increased vein graft apoptosis. We have previously reported that arterialization results in medial cell apoptosis 8 h and 1 day after vein grafting (14) . UO126 treatment also resulted in significant apoptosis at 4 days, a time when apoptosis starts fading in vein grafts that were not treated with the MEK-1/2 inhibitor (14).
Attempts to identify endothelial cells in canine veins by immunostaining with anti-CD31 or anti-VWF antibodies were unsuccessful. Therefore, to characterize the cellular components of our vein grafts and control veins, we used transmission electron microscopy. This analysis showed that most of the endothelial cell layer of the arterialized vein grafts was absent (Supplemental Fig. 3 ). In contrast, the smooth muscle cells of arterialized vein grafts showed an abundant rough endoplasmic reticulum, an indication of active protein synthesis. Colocalization studies showed that TUNEL-positive cells were interspersed within the α-SMC actin-positive layer, indicating that the apoptosis observed at day 4 occurred among medial smooth muscle cells (Supplemental Fig. 4 ).
Pretreatment with UO126 inhibits vein graft infiltration by inflammatory cells but not upregulation of vein graft-associated CRP levels
Vascular injury is associated with a variable degree of inflammation (19) . We have found that in our animal model, high levels of thrombin; tumor necrosis factor (TNF)-α; MPO, a marker of PMN infiltration (unpublished results); and CRP are associated with arterialized vein grafts (unpublished results). Vein graft-associated MPO levels rise within hours after the operation (unpublished results), whereas CRP levels, negligible at 3 h, are elevated at 24 h both in serum and in arterialized vein graft (unpublished results). Therefore, we tested the effect of MAPK inhibition on MPO and CRP up-regulation within the arterialized vein graft. UO126 pretreatment dramatically decreased the levels of vein graft-associated MPO (Fig. 3A) and virtually abolished vein graft infiltration by MPO-positive cells (Fig. 3B) . The inhibitor seemed to have no significant effect at day 1. In contrast, pretreatment with UO126 did not affect the levels of vein graft-associated CRP (Fig. 3C) .
DISCUSSION
Vascular remodeling and neointimal formation after vein graft arterialization are marked by inflammatory responses and by increased smooth muscle cell proliferation and migration. These effects represent an overly exuberant response of the vein wall to arterial pressure and flow rate and are often followed by significantly flow-limiting stenosis and predisposition to atherosclerotic changes (20) . Vein graft failure is promoted by a variable degree of endothelial damage, proliferation and migration of medial smooth muscle cells into the lumen, deposition of abundant extracellular matrix, and, ultimately, formation of a neointima. MAPKs have been identified as key biosensors of vascular injury following vein graft arterialization (14, 21) .
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Attempts have therefore been made to reduce intimal hyperplasia by inhibiting intracellular signaling mediated by MAPK. In a rat carotid artery injury model, partial MAPK inhibition was obtained with a blocking antibody to rat endogenous FGF-2 or a first-generation inhibitor of MAPK activation, PD98059. Both treatments reduced the proliferative response of the carotid artery's medial cells (10) . Similarly, gene therapy with dominant-negative mutants of components of the ERK and JNK pathways blocked both medial cell proliferation and intimal hyperplasia following arterial injury (11) . However, general concerns about systemic and longterm effects of gene therapy prompt the search for alternative, safer pharmacological approaches.
Our data indicate that MAPK activation plays a pivotal role in controlling the initial events leading to medial cell activation. In light of the involvement of ERK-1/2 activation in the control of vascular cell migration (12, 13) , one could expect that UO126 pretreatment of vein grafts will also prevent medial cell migration.
The use of inhibitors of cell functions within vascular conduits subjected to surgical injury raises concerns not only regarding the effectiveness of treatment on early graft stenosis but also the potential threat of thrombosis on early, mid-to long-term conduit patency. The recent case reports of failure of coated stents illustrate the nature of such concerns (22) . Our finding that MAPK inhibition reduces early inflammatory cell infiltration indicates an additional potential benefit of UO126 pretreatment. Because the ERK-1/2 pathway has been implicated in regulating adhesion molecules (23) , this effect could be explained by a concomitant, reduced expression of adhesion molecules involved in leukocyte transmigration into blood vessels. Our observation of an anti-inflammatory effect of UO126 is also consistent with its capacity to reduce eosinophilia in a mouse asthma model (24) .
Our results show that increased levels of vein graft-associated CRP, an acute phase reactant recently implicated as a major risk factor in cardiovascular disorders (25) , are not affected by UO126 pretreatment. CRP is produced by the liver under pro-inflammatory conditions and released into the blood circulation where it can reach levels up to 100-fold as high as under normal conditions (26) . Although CRP can be synthesized within atherosclerotic vessels (27) , the high levels of CRP found in vein graft appear to be the result of its diffusion from the circulation into injured vessels (unpublished results). However, it is also possible that UO126 pretreatment, although unable to prevent the rise of CRP levels observed in vein graft, could prevent some of the demonstrated CRP effects that are under the control of MAPK activation (28) .
We unexpectedly found that brief incubation with UO126, a relatively short-lived MAPK inhibitor, of the vein segment to be grafted affects medial smooth muscle cell proliferation and apoptosis days after arterialization. This finding is consistent with previous observations of phases of signaling pathway activation triggered by a single stimulus in a number of experimental systems (9, 14, 29) . Indeed, some growth factors involved in vascular remodeling, such as FGF-2 and VEGF, act in series rather than in parallel (30) , thus generating a cascade of intracellular signaling events. Inhibition of the initial event of ERK-1/2 activation can therefore result in blockade of the downstream cascade.
We investigated the possibility that, in addition to inhibiting ERK-1/2 activation, UO126 pretreatment could affect other signaling pathways that control cell survival. The results showed that Akt phosphorylation, an event usually linked to apoptosis inhibition, was induced at 3 h in arterialized vein grafts and was not affected by preincubating the vein grafts with UO126. Thus, the apoptosis we observed in UO126-treated arterialized vein grafts does not result from a nonspecific effect of the inhibitor. Our analysis of apoptosis showed that in UO126-treated vein grafts TUNEL reactivity colocalized with the smooth muscle cell marker, α-SMC actin, indicating that UO126 up-regulates apoptosis in the medial smooth muscle cells. Electron microscopic analysis showed absence of intimal layer in control vein grafts not treated with UO126. Thus, we cannot conclude whether UO126 treatment would also affect the endothelium of arterialized vein graft. However, UO126 concentrations that completely abrogate ERK-1/2 activation in cultured endothelial cells do not induce apoptosis even during long-term culture (unpublished observations).
The approach described here provides a more efficient method of MAPK inhibition than those used in arterial injury models. Because the veins are incubated with the synthetic MAPK inhibitor ex vivo before grafting, the risks of potential systemic effects of the inhibitor are negligible. In addition, ex vivo treatment affords a convenient method of drug delivery during bypass graft surgery, in which vein grafts are routinely incubated in physiologic solution during the time between excision and implantation.
A number of considerations make our pharmacological approach applicable to clinical settings. First, the delivery method of the inhibitor considerably reduces the risks associated with systemic effects, while maintaining its effectiveness locally. Second, the ex vivo administration of UO126 does not interfere with most routine surgical procedures. Finally, the early inhibition of the MAPK pathway modulates key events of vascular remodeling, such as apoptosis and cell proliferation, favoring decreased cellularity of the vein graft in the short term. At the same time, it also inhibits early PMN infiltration into the vein graft, which may promote a favorable outcome of vascular remodeling following injury. Therefore, inhibition of MAPK pathways could be used to blunt the first wave of events following vein graft arterialization. By contrast, prolonged inhibition of the same pathways, for example by means of a gene therapy approach, could limit the potential recovery of the injured endothelium, by blocking endothelial cell migration and proliferation from the anastomosed artery (12, 13 ).
Here we show that inhibition of arterialization-induced activation of ERK-1/2 by a clinically applicable method blocks vein graft medial cell proliferation and produces sustained increase of medial cell apoptosis. Simple pretreatment of the vein graft with UO126, a synthetic inhibitor of ERK-1/2 activation, alters the balance between cell proliferation and programmed death within the vessel wall. Altering the balance between medial cell proliferation and apoptosis has been shown to be an effective tool for reducing the development of intimal hyperplasia following arterial (31) or vein graft (32) injury. Our results, therefore, indicate a novel pharmacological tool for modulating cell functions involved in vein graft disease.
In conclusion, the results presented here support the role of MAPKs in controlling medial cell proliferation and apoptosis in arterialized vein grafts. The MEK-1/2 inhibitor UO126 both reduces arterialization-induced cell proliferation and exacerbates medial cell apoptosis while blocking, at least in part, the early inflammatory response that follows vascular injury. These results suggest a safe therapeutic tool for reducing the early pathologic response of vein grafts to arterialization and, ultimately, late vein graft failure. Tissue extracts obtained from control femoral vein (C) and from arterialized vein graft pretreated with 0.8% (v/v) DMSO (AVG) or with 80 µmol/l of UO126 (UO) at 3 h and 1 day were analyzed by Western blotting using a polyclonal antibody to MPO (upper panel). The same membrane was then probed with a polyclonal antibody to ERK-2 for loading and transfer control (lower panel). B) Cross-sections of the veins obtained from the same experiments were analyzed by immunohistochemistry using the same anti-MPO antibody. MPO-positive cells line the tunica intima of DMSO-treated vein grafts, whereas UO126 treatment resulted in a strong decrease of MPO-positive cells at 3 h. No significant difference was detected at 1 day. Bar = 100 µm. C) Tissue extracts obtained from control femoral vein (C) and from arterialized vein graft pretreated with 0.8% (v/v) DMSO (AVG) or with 80 µmol/l of UO126 (UO) at 1 day were analyzed by Western blotting using a polyclonal antibody to CRP (upper panel). The same membrane was then probed with a polyclonal antibody to ERK-2 for loading and transfer control (lower panel). This analysis shows that inhibition of the ERK-1/2 pathway does not affect CRP increase in the arterialized vein graft. This experiment was repeated at least three times with comparable results.
